All hypertension is shaped upstream, within the intricate interplay of mechanisms that regulate arterial tone, sodium and water balance, and the activity of the renin–angiotensin–aldosterone system. For decades, pharmacology has acted mainly downstream, attempting to lower blood pressure once the current was already running strong. New molecules are now pointing toward a different strategy, tracing the river back toward some of its biological sources and interrupting the signal before it spreads.
The scale of the problem is striking. In 2024, an estimated 1.4 billion adults aged 30 to 79 were living with hypertension worldwide, according to the World Health Organization. Yet only about 320 million had their blood pressure under control. In the United States, the most recent data indicate that roughly three out of four adults with hypertension do not have their blood pressure under control according to the 130/80 mmHg threshold.
Within this vast population lies a particularly complex subset, resistant hypertension, which persists despite treatment with three antihypertensive agents from different classes, including a diuretic, administered at optimal or maximally tolerated doses. Some of the most compelling pharmacological innovations of recent years are being developed in this therapeutically challenging territory.
The first pathway targets aldosterone, a hormone that promotes renal retention of sodium and water and contributes to raising blood pressure. A substantial proportion of patients with resistant hypertension have inappropriately elevated aldosterone production. Aldosterone synthase inhibitors act directly on the enzyme responsible for its synthesis rather than blocking its receptor. Their high selectivity helps preserve cortisol synthesis, overcoming one of the main obstacles that limited the development of earlier inhibitors.
Baxdrostat is the first of this new generation to cross the U.S. regulatory threshold. The FDA approved it on May 15, 2026, for the treatment of hypertension in combination with other antihypertensive agents. In a phase III trial published in The New England Journal of Medicine, it produced an additional reduction in systolic blood pressure of 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg at 12 weeks, compared with placebo.
Lorundrostat, another selective aldosterone synthase inhibitor, is also far advanced. The FDA accepted its application for regulatory review and set December 22, 2026, as the target date for its decision. In a trial likewise published in The New England Journal of Medicine, it produced additional reductions in ambulatory systolic blood pressure of approximately 6.5 to 7.9 mmHg compared with placebo.
The second pathway reaches an even deeper level. Instead of acting on an already formed hormone or its receptor, it intervenes in the hepatic production of angiotensinogen, the protein that initiates the renin–angiotensin cascade. Zilebesiran uses RNA interference to silence the messenger RNA encoding this protein over an extended period. It is the quiet act of pausing the command before it is ever spoken.
Its main appeal lies in the duration of its effect. The phase III ZENITH trial administers zilebesiran as a subcutaneous injection every six months, as an add-on to standard antihypertensive therapy. The study examines whether this strategy reduces the incidence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and heart-failure events. Follow-up will continue until the number of events required to evaluate these outcomes is reached.
The possibility of spacing administrations has clear clinical relevance. Adherence is one of the major challenges of antihypertensive treatment, especially when it requires daily medication for decades. Replacing hundreds of annual doses with two scheduled administrations could facilitate adherence, although its true impact on adherence and, above all, on cardiovascular events remains to be demonstrated.
Completing this new map are aprocitentan, an endothelin receptor antagonist approved in the United States in 2024 for patients whose hypertension is not adequately controlled with other treatments, and investigational molecules such as ocedurenone, a nonsteroidal mineralocorticoid receptor antagonist that has shown blood-pressure reductions in patients with chronic kidney disease and uncontrolled or resistant hypertension.
But it is essential to maintain perspective. Pharmacological innovation does not displace the foundations of blood-pressure control, including a healthy diet, reduced sodium intake, physical activity, maintenance of a healthy weight, and moderation of alcohol consumption. The new drugs expand the therapeutic arsenal where lifestyle measures and available treatments are not enough.
Each 5 mmHg reduction in systolic blood pressure decreases the risk of major cardiovascular events by roughly 10%. A reduction of 10 mmHg therefore approaches a relative risk reduction of 20%, although the exact effect depends on the clinical context and should not be interpreted as a rigid mathematical relationship.
Medicine is thus learning to move upstream, to search closer to the origin of the signals that raise blood pressure, and to intervene with increasing precision. The ultimate goal remains unchanged, to protect the heart, the brain, the kidneys, and, ultimately, the pulse that sustains us.
Today’s research is tomorrow’s therapy